Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
NCT07896434 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
- Lead sponsor
- AbbVie
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 28, 2027
- Completion date
- August 31, 2032
- Enrollment
- 154 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
non-segmental vitiligo
Arms
As registered; 2 arms.
-
Period A: Double-Blind Treatment Period
Pediatric participants will receive an adult-equivalent dose of upadacitinib or a matching placebo dose
-
Period B: Blinded Extension Period
Pediatric participants who complete Period A will continue into Period B and remain on blinded treatment.
Pediatric participants initially randomized to blinded placebo (Period A) who have not achieved F-VASI 75 at Week 48 (nonresponders) will receive a blinded upadacitinib adult dose equivalent in Period B.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline)
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.
-
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Lead sponsor's other trials
AbbVie, most recent start first.
+1,194 more trials See the organization page